Exelixis (EXEL) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vaxcyte (PCVX) has outperformed Exelixis (EXEL) over the past year, gaining 59.9% versus a gain of 47.5%. Over five years, PCVX leads with a +174.3% price change compared with +167.8% for EXEL. Exelixis is the larger company by market cap ($14.48 billion vs $9.96 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | PCVX |
|---|---|---|
| Share price | $58.44 | $66.96 |
| Market cap | $14.48B | $9.96B |
| 1-day change | +0.19% | +0.39% |
| YTD return | +33.33% | +45.12% |
| 1-year return | +47.46% | +59.92% |
| 5-year return | +167.83% | +174.31% |
| P/E ratio (TTM) | 18.38 | — |
| Forward P/E | 13.78 | — |
| EPS (TTM) | $3.18 | $-7.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | — |
| Revenue growth (YoY) | +6.98% | — |
| Net income (latest FY) | $782.57M | $-766.63M |
| Gross margin | 96.39% | — |
| Operating margin | 37.59% | — |
| Net margin | 33.73% | — |
| 52-week high | $61.14 | $90.75 |
| 52-week low | $33.76 | $39.87 |
| Distance from 52-week high | -4.42% | -26.21% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -6.69% | +65.59% |
| Average volume | 2.33M | 1.50M |
| Shares outstanding | 247.78M | 148.81M |
| Employees | 1,077 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCVX has outperformed EXEL by 12.5 percentage points over the past year.
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
EXEL vs PCVX FAQ
Which is bigger, Exelixis or Vaxcyte?
Exelixis (EXEL) is larger, with a market capitalization of $14.48B compared with $9.96B for Vaxcyte (PCVX).
Which stock has performed better over the past year, EXEL or PCVX?
PCVX returned +59.92% over the past 12 months, compared with +47.46% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Are Exelixis and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.